Aarey Drugs & Pharmaceuticals Board Approves Q2 and H1 FY26 Unaudited Financial Results
Aarey Drugs & Pharmaceuticals Board approved Q2 and H1 FY26 unaudited financial results, showing a decline in revenue and net profit compared to the previous year.
The announcement of unaudited financial results is a significant event for investors, providing insight into the company's performance. The reported decline in key financial metrics is noteworthy but not severe enough to warrant a 'HIGH' impact without further context on market expectations or future guidance.
The company reported a decrease in both revenue from operations and net profit for the quarter and half-year ended September 30, 2025, compared to the corresponding periods in the previous year, indicating a negative financial performance.
* The Board of Directors of Aarey Drugs & Pharmaceuticals Limited met on November 13, 2025, and approved the unaudited financial results for the quarter and half year ended September 30, 2025. * Key financial highlights for the quarter ended September 30, 2025, compared to the previous year: * Revenue from operations decreased to ₹10,220.83 lakhs from ₹10,514.36 lakhs. * Net profit decreased to ₹102.38 lakhs from ₹159.65 lakhs. * Earnings Per Share (EPS) decreased to ₹0.36 from ₹0.57. * Key financial highlights for the half year ended September 30, 2025, compared to the previous year: * Revenue from operations slightly decreased to ₹23,205.54 lakhs from ₹23,365.04 lakhs. * Net profit decreased to ₹239.51 lakhs from ₹283.56 lakhs. * Earnings Per Share (EPS) decreased to ₹0.84 from ₹1.01. * The independent auditor's review report noted that the company purchased certain fixed assets during the reporting period that are not yet ready for their intended use. Accordingly, no depreciation has been charged on these assets for the current period, and it will commence once they are fully installed and commissioned. * The meeting commenced at 5:30 p.m. and concluded at 8:20 p.m. on November 13, 2025.
What to do with a filing like this
Aarey Drugs & Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Aarey Drugs & Pharmaceuticals Limited. Read the original for the full detail.